[go: up one dir, main page]

WO2008135671A3 - Dérivés de la classe des hydroxyquinoléines aminées pour le traitement de cancers. - Google Patents

Dérivés de la classe des hydroxyquinoléines aminées pour le traitement de cancers. Download PDF

Info

Publication number
WO2008135671A3
WO2008135671A3 PCT/FR2008/000399 FR2008000399W WO2008135671A3 WO 2008135671 A3 WO2008135671 A3 WO 2008135671A3 FR 2008000399 W FR2008000399 W FR 2008000399W WO 2008135671 A3 WO2008135671 A3 WO 2008135671A3
Authority
WO
WIPO (PCT)
Prior art keywords
aminated
derivatives
treating cancers
hydroxyquinoline class
hydroxyquinoline
Prior art date
Application number
PCT/FR2008/000399
Other languages
English (en)
Other versions
WO2008135671A2 (fr
Inventor
Jean-Louis Kraus
Olivier Blin
Frederic Champavere
Original Assignee
Biopharmed Sarl
Jean-Louis Kraus
Olivier Blin
Frederic Champavere
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biopharmed Sarl, Jean-Louis Kraus, Olivier Blin, Frederic Champavere filed Critical Biopharmed Sarl
Priority to CA002680803A priority Critical patent/CA2680803A1/fr
Priority to JP2009554065A priority patent/JP5555494B2/ja
Priority to EP08787845A priority patent/EP2139860A2/fr
Priority to CN200880007473.7A priority patent/CN101641332B/zh
Priority to AU2008248475A priority patent/AU2008248475B2/en
Priority to US12/532,695 priority patent/US8324243B2/en
Publication of WO2008135671A2 publication Critical patent/WO2008135671A2/fr
Publication of WO2008135671A3 publication Critical patent/WO2008135671A3/fr
Priority to US13/690,137 priority patent/US8614230B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention se rapporte à des composés de type hydroxyquinoléines aminées présentant une capacité à empêcher la migration de métastases ou de cellules tumorales. De tels composés sont utiles pour le traitement de cancers.
PCT/FR2008/000399 2007-03-23 2008-03-25 Dérivés de la classe des hydroxyquinoléines aminées pour le traitement de cancers. WO2008135671A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002680803A CA2680803A1 (fr) 2007-03-23 2008-03-25 Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers
JP2009554065A JP5555494B2 (ja) 2007-03-23 2008-03-25 癌を治療するためのアミノ化ヒドロキシキノリン類誘導体
EP08787845A EP2139860A2 (fr) 2007-03-23 2008-03-25 Dérivés de la classe des hydroxyquinoléines aminées pour le traitement de cancers.
CN200880007473.7A CN101641332B (zh) 2007-03-23 2008-03-25 用于治疗癌症的胺化的羟基喹啉类衍生物
AU2008248475A AU2008248475B2 (en) 2007-03-23 2008-03-25 Derivatives of the aminated hydroxyquinoline class for treating cancers
US12/532,695 US8324243B2 (en) 2007-03-23 2008-03-25 Derivatives of the aminated hydroxyquinoline class for treating cancers
US13/690,137 US8614230B2 (en) 2007-03-23 2012-11-30 Derivatives of the aminated hydroxyquinoline class for treating cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR07/02154 2007-03-23
FR0702154A FR2913976B1 (fr) 2007-03-23 2007-03-23 Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/532,695 A-371-Of-International US8324243B2 (en) 2007-03-23 2008-03-25 Derivatives of the aminated hydroxyquinoline class for treating cancers
US13/690,137 Continuation US8614230B2 (en) 2007-03-23 2012-11-30 Derivatives of the aminated hydroxyquinoline class for treating cancers

Publications (2)

Publication Number Publication Date
WO2008135671A2 WO2008135671A2 (fr) 2008-11-13
WO2008135671A3 true WO2008135671A3 (fr) 2009-05-22

Family

ID=38686734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000399 WO2008135671A2 (fr) 2007-03-23 2008-03-25 Dérivés de la classe des hydroxyquinoléines aminées pour le traitement de cancers.

Country Status (8)

Country Link
US (2) US8324243B2 (fr)
EP (1) EP2139860A2 (fr)
JP (1) JP5555494B2 (fr)
CN (1) CN101641332B (fr)
AU (1) AU2008248475B2 (fr)
CA (1) CA2680803A1 (fr)
FR (1) FR2913976B1 (fr)
WO (1) WO2008135671A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2913976B1 (fr) * 2007-03-23 2013-04-26 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.
EP2149567A1 (fr) * 2008-07-18 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Composé pour la liaison de phosphatidylsérine
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
KR101514285B1 (ko) 2013-08-09 2015-04-22 숙명여자대학교산학협력단 아미노다이하이드로퀴놀린 화합물 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 암 질환의 예방 또는 치료용 약학적 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074664A2 (fr) * 1999-06-07 2000-12-14 Yeda Research And Development Co. Ltd. Compositions pharmaceutiques comprenant des agents chelateurs de fer destinees au traitement de troubles neurodegeneratifs et nouveaux agents chelateurs de fer
CN1594328A (zh) * 2004-06-18 2005-03-16 中国科学院广州化学研究所 单官能团8－羟基喹啉金属配合物的烯类单体及其制法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5736192A (en) * 1980-08-13 1982-02-26 Nippon Oil Co Ltd Metal inactivator and its composition
CA2505476C (fr) * 2002-11-07 2015-05-26 Technion Research And Development Foundation Ltd. Chelateurs du fer et compositions pharmaceutiques les renfermant
FR2913976B1 (fr) * 2007-03-23 2013-04-26 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement de cancers.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000074664A2 (fr) * 1999-06-07 2000-12-14 Yeda Research And Development Co. Ltd. Compositions pharmaceutiques comprenant des agents chelateurs de fer destinees au traitement de troubles neurodegeneratifs et nouveaux agents chelateurs de fer
CN1594328A (zh) * 2004-06-18 2005-03-16 中国科学院广州化学研究所 单官能团8－羟基喹啉金属配合物的烯类单体及其制法和用途

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
ARZNEIMITTEL-FORSCHUNG , 23(2), 285-6 CODEN: ARZNAD; ISSN: 0004-4172, 1973 *
BURCKHALTER, J. H. ET AL: "Amino- and chloromethylafion of 8-quinolinol. Mechanism of preponderant ortho substitution in phenols under Mannich conditions", JOURNAL OF ORGANIC CHEMISTRY , 26, 4078-83 CODEN: JOCEAH; ISSN: 0022-3263, 1961, XP002460956 *
CREECH H. J. ET AL: "Quantitative Studies of the Effects of Nitrogen Mustard Analogs and Other Alkylating Agents on Ascites Tumors in Mice", CANCER RESEARCH, vol. 20, no. 7(Part.2), 1 August 1960 (1960-08-01), pages 471 - 494, XP002460958, ISSN: 0008-5472 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1004, ZHAO, XIAOJUN ET AL: "Synthesis and characterization of novel N-functionalized macrocyclic dioxotetraamines bearing 8-hydroxyquinoline and its metal complexes: Stability in aqueous solutions", XP002460962, retrieved from STN Database accession no. 2004:818724 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1973, NARDI, D. ET AL: "Antimicrobial activity of some 7-nitro- and 7-aminodialkylaminomethyl-8- hydroxyquinolines", XP002460960, retrieved from STN Database accession no. 1973:147760 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2005, DU, NAIYING ET AL: "Monofunctional 8-hydroxyquinoline metal complex-containing olefin monomers and their preparation and application", XP002460961, retrieved from STN Database accession no. 2006:136201 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CHOUGH, YUN-SUNG: "Synthesis of chemotherapeutic agents with 2- and 4-(2- dialkylaminoethyl)piperidines with N,N-bis(2-chloroethyl)-amine side chains", XP002460964, retrieved from STN Database accession no. 1960:68227 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PATEL, S. P. ET AL: "Coordination polymers of N,N'-di-(8-hydroxyquinolinol yl-5-methyl)-N,N' dimethyl-1,2-ethane diamine (QMED)", XP002460963, retrieved from STN Database accession no. 2005:1159137 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHEN, AI-YU ET AL: "Synthesis and cytotoxicity evaluation of some 8-hydroxyquinoline derivatives", XP002460959, retrieved from STN Database accession no. 1999:446271 *
GAL, SHUNIT ET AL: "Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion", JOURNAL OF NEUROCHEMISTRY , 95(1), 79-88 CODEN: JONRA9; ISSN: 0022-3042, 2005, XP002460954 *
INDIAN JOURNAL OF CHEMISTRY, SECTION A: INORGANIC, BIO-INORGANIC, PHYSICAL, THEORETICAL & ANALYTICAL CHEMISTRY , 43A(4), 793-798 CODEN: ICACEC; ISSN: 0376-4710, 2004 *
JOURNAL OF PHARMACY AND PHARMACOLOGY , 51(5), 543-548 CODEN: JPPMAB; ISSN: 0022-3573, 1999 *
LI, XINGWEI ET AL: "Conducting poly-N-[5-(8-quinolinol)ylmethyl]aniline/nano-SiO2 composite with fluorescence", MATERIALS LETTERS , 60(28), 3342-3345 CODEN: MLETDJ; ISSN: 0167-577X, 2006, XP005720529 *
MARJAN KOLOBIELSKI: "The synthesis of substituted 8-quinolinols", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 101, no. 6, 1968, pages 275 - 277, XP002460953 *
MISHRA, AMARESH ET AL: "Synthesis and characterization of soluble aluminum complex dyes based on 5-substituted-8-hydroxyquinoline derivatives for OLED applications", DYES AND PIGMENTS , 66(2), 89-97 CODEN: DYPIDX; ISSN: 0143-7208, 2005, XP002460955 *
MISHRA, AMARESH ET AL: "Synthesis of 5-alkoxymethyl- and 5-aminomethyl-substituted 8-hydroxyquinoline derivatives and their luminescent Al(III) complexes for OLED applications", TETRAHEDRON LETTERS , 45(33), 6265-6268 CODEN: TELEAY; ISSN: 0040-4039, 2004, XP004817737 *
MORET, VINCENT ET AL: "Synthesis and anti-HIV properties of new hydroxyquinoline-polyamine conjugates on cells infected by HIV-1 LAV and HIV-1 BaL viral strains", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 16(23), 5988-5992 CODEN: BMCLE8; ISSN: 0960-894X, 2006, XP005850587 *
OLOFF, SCOTT ET AL: "Application of Validated QSAR Models of D1 Dopaminergic Antagonists for Database Mining", JOURNAL OF MEDICINAL CHEMISTRY , 48(23), 7322-7332 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP002460952 *
SEOUL UNIV. J. , 8, 335-58, 1959 *
ULTRA SCIENTIST OF PHYSICAL SCIENCES , 17(2), 247-252 CODEN: USPSE5, 2005 *
WARNER, VICTOR D. ET AL: "Quantitative structure-activity relations for 5-substituted 8-hydroxyquinolines as inhibitors of dental plaque", JOURNAL OF MEDICINAL CHEMISTRY , 20(1), 92-6 CODEN: JMCMAR; ISSN: 0022-2623, 1977, XP002163946 *
ZHENG, HAILIN ET AL: "Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases", BIOORGANIC & MEDICINAL CHEMISTRY , 13(3), 773-783 CODEN: BMECEP; ISSN: 0968-0896, 2005, XP004710842 *

Also Published As

Publication number Publication date
CA2680803A1 (fr) 2008-11-13
WO2008135671A2 (fr) 2008-11-13
US8614230B2 (en) 2013-12-24
JP5555494B2 (ja) 2014-07-23
US20100120856A1 (en) 2010-05-13
AU2008248475A1 (en) 2008-11-13
EP2139860A2 (fr) 2010-01-06
FR2913976A1 (fr) 2008-09-26
JP2010522147A (ja) 2010-07-01
CN101641332A (zh) 2010-02-03
US8324243B2 (en) 2012-12-04
CN101641332B (zh) 2014-03-12
FR2913976B1 (fr) 2013-04-26
AU2008248475B2 (en) 2013-10-03
US20130102630A1 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
WO2009046841A8 (fr) Dérivés de pipéridine et de pipérazine
WO2008124660A3 (fr) Procédés et compositions pour le traitement du cancer
AU2016204376A1 (en) MicroRNA-based methods and compositions for the diagnosis and treatment of ovarian cancer
WO2008079988A3 (fr) Quinazolines destinés à l'inhibition de pdk1
WO2008128072A3 (fr) Inhibiteurs de la kinase axl
UA109775C2 (xx) N-вмісні гетероарильні похідні як інгібітори jak3-кінази
WO2009046842A3 (fr) Dérivés de thiazole
WO2007101551A3 (fr) Complexes phospholipidiques de curcumine présentant une biodisponibilité améliorée
JO2778B1 (en) Certain Compounds, Compositions and Methods
WO2008104806A3 (fr) Protéine
WO2009006389A8 (fr) Composés utiles en tant qu'inhibiteurs de la kinase raf
WO2007123892A3 (fr) Inhibiteurs raf et leurs utilisations
WO2009073153A3 (fr) Inhibiteurs myristate à petites molécules de bcr-abl et procédés d'utilisation
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2011031896A3 (fr) Inhibiteurs de pi3 kinase et leurs utilisations
HK1208151A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
TW200700414A (en) Novel pharmaceutical compounds
WO2009129267A3 (fr) Inhibiteurs de petites molécules du domaine d'homologie de la pleckstrine, et leurs méthodes d'utilisation
WO2007120574A3 (fr) Alcanes à substitution diaryle
WO2010068292A8 (fr) Dérivés d'azaindole en tant qu'inhibiteurs de kinases
WO2013158373A8 (fr) Dérivés d'indolin-2-one à titre d'inhibiteurs de protéines kinases
WO2006128455A3 (fr) Composes modifiant l'apoptose
WO2009092108A3 (fr) Biomarqueurs pour le diagnostic et le traitement du cancer du pancréas
MX2008001538A (es) Aril piridinas y metodos para su uso.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880007473.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08787845

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008248475

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2680803

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1729/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009554065

Country of ref document: JP

REEP Request for entry into the european phase

Ref document number: 2008787845

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008787845

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2008248475

Country of ref document: AU

Date of ref document: 20080325

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12532695

Country of ref document: US